Insider Trading Activity For United Therapeutics Corporation (NASDAQ:UTHR)
Martine A Rothblatt , CEO of United Therapeutics Corporation (NASDAQ:UTHR) reportedly Sold 2,176 shares of the company’s stock at an average price of 127.11 for a total transaction amount of $276,591.36 SEC Form
Insider Trading History For United Therapeutics Corporation (NASDAQ:UTHR)
Analyst Ratings For United Therapeutics Corporation (NASDAQ:UTHR)
These are 3 Sell Ratings, 7 Hold Ratings, 2 Buy Ratings .
The current consensus rating for United Therapeutics Corporation (NASDAQ:UTHR) is Hold (Score: 1.92) with a consensus target price of $134.70 , a potential (5.05% upside)
Analyst Ratings History For United Therapeutics Corporation (NASDAQ:UTHR)
- On 4/11/2016 Royal Bank Of Canada Reiterated Rating Sector Perform with a price target of $150.00 to $122.00
- On 8/23/2016 Argus Reiterated Rating Hold
- On 11/29/2016 Barclays PLC Downgraded rating Equal Weight to Underweight with a price target of $115.00 to $100.00
- On 1/19/2017 Standpoint Research Downgraded rating Buy to Hold
- On 2/23/2017 Leerink Swann Boost Price Target of rating Market Perform with a price target of $127.00 to $148.00
- On 2/23/2017 Ladenburg Thalmann Financial Services Downgraded rating Buy to Neutral with a price target of $145.00
- On 4/3/2017 Credit Suisse Group Reiterated Rating Underperform with a price target of $120.00
Recent Trading Activity for United Therapeutics Corporation (NASDAQ:UTHR)
Shares of United Therapeutics Corporation closed the previous trading session at 128.23 up +1.21 0.95% with 711,369 shares trading hands.